On February 1, 2022 Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, and CantonBio Deutschland GmbH, a subsidiary of Canton Biologics Co. Ltd., a leading Chinese CDMO, reported the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH (Press release, Glycotope, FEB 1, 2022, View Source [SID1234607597]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The spin-out completes Glycotope’s refocus solely towards drug discovery and development, utilizing its proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. FyoniBio, now as part of Canton Biologics Group, will continue the contract development service business and offer a broad range of ISO-9001 compliant services from cell line development to clinical bioanalysis.
Henner Kollenberg, Glycotope’s Chief Executive Officer, said "We look forward to collaborating with FyoniBio for our development needs, while Glycotope’s renewed focus solely on drug discovery and development sharpens our profile as a platform company for tumor targeting antibodies with unique specificity."
Dr. Lars Stöckl, Managing Director of FyoniBio said "We are also looking forward to continuing the service business with a great team of long-term colleagues and long-standing existing partners as well as potential new collaborators."
Dr. Hans Baumeister, Managing Director of FyoniBio added; "We are so happy to be able to offer extended one-stop service packages from clone and cell line development all the way to GMP manufacturing. Our portfolio in clinical bioassay services performed under GCLP quality regulations is surely an add-on for the CDMO service offered by FyoniBio and Canton Biologics."
Dr. Xiao Shen, Founder and Chief Executive Officer of Canton Biologics said, "The acquisition of FyoniBio not only supports the international growth strategy of Canton Biologics, more importantly, through FyoniBio, Canton Biologics can significantly extend our technology platforms and service scope to better support international clients in Europe and worldwide."